Latest Tocagen Inc. Stories

2014-08-26 08:30:47

Names Wayne Saville, M.D., Vice President, Clinical Development, and Mary Rose Keller Vice President, Clinical Operations SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Tocagen Inc. today announced Wayne Saville, M.D., has been named vice president, clinical development, and Mary Rose Keller has been named vice president, clinical operations. "As we advance Toca 511 & Toca FC into late-stage registration studies, we are expanding our clinical team with individuals who have deep...

2014-05-22 08:29:48

In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ -- Tocagen Inc. today announced multiple scientific contributions at the American Society of Gene and Cell Therapy (ASGCT) 17(th) Annual Meeting, held May 21 to 24, 2014 at the Marriott Wardman Park in Washington, DC. At the ASGCT Annual Meeting, data from clinical and preclinical studies of Toca 511 will be presented in two podium presentations:...

2014-04-10 08:29:39

Results Continue to Show Safety and Promising Survival; Program to Advance into a Randomized, Controlled Trial SAN DIEGO, April 10, 2014 /PRNewswire/ -- Tocagen Inc. today announced that updated interim clinical data from two ongoing investigational studies of Toca 511 in combination with Toca FC in 68 patients with recurrent high grade glioma were presented at the American Association of Neurological Surgeons (AANS) Annual Meeting in San Francisco. High grade gliomas include...

2014-03-25 08:29:38

Pharmaceutical Executive Brings Additional Expertise in Oncology Drug Development and Commercialization SAN DIEGO, March 25, 2014 /PRNewswire/ -- Tocagen Inc. today announced that Jamey Skillings, M.D., has been named Senior Vice President and Chief Medical Officer. Dr. Skillings joins Tocagen from Pfizer, where she was most recently vice president of global medical affairs for oncology. Dr. Skillings' clinical leadership at prior pharmaceutical companies led to several oncology...

2014-03-11 08:29:44

Intravenous Delivery Is An Important Advancement in the Development of Toca 511, Creates Opportunity For Use In Additional Cancer Indications SAN DIEGO, March 11, 2014 /PRNewswire/ -- Tocagen Inc. today announced that the first patient has been dosed in its clinical trial investigating the intravenous administration of selective cancer therapy Toca 511 & Toca FC, in patients with recurrent high grade glioma (HGG) including glioblastoma multiforme (GBM, Grade 4 HGG), the most...

2013-07-02 23:18:27

Study investigated treatment for canine brain tumors while aiding development of potential new therapy for humans. Chicago, IL (PRWEB) July 02, 2013 The American Brain Tumor Association (ABTA) today announced highlights from the final report on a grant supporting clinical research of naturally-occurring canine brain tumors to discover more effective methods of treatment for human brain tumors. The $200,000 grant was awarded by the ABTA in 2011 to San Diego-based Tocagen, Inc. for the...

Word of the Day
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).